
Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC
Subcutaneous (SC) pembrolizumab (Keytruda; pembrolizumab with berahyaluronidase alfa) was noninferior to intravenous (IV) pembrolizumab with respect to cycle 1 overall exposure and steady-state trough concentration in patients with treatment-naive, …